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ABSTRACT
Background. Poly(ADP-ribose) polymerase inhibitors (PARPis)
are U.S. Food and Drug Administration (FDA) approved for
treatment of BRCA-mutated metastatic breast cancer. Further-
more, the BROCADE studies demonstrated benefit of adding
an oral PARPi, veliparib, to carboplatin and paclitaxel in
patients with metastatic breast cancer harboring BRCA muta-
tion. Given multiple possible dosing schedules and the poten-
tial benefit of this regimen for patients with defective DNA
repair beyond BRCA, we sought to find the recommended
phase II dose (RP2D) and schedule of veliparib in combination
with carboplatin in patients with advanced breast cancer,
either triple-negative (TNBC) or hormone receptor (HR)-posi-
tive, human epidermal growth receptor 2 (HER2) negative with
defective Fanconi anemia (FA) DNA-repair pathway based on
FA triple staining immunofluorescence assay.
Materials and Methods. Patients received escalating doses of
veliparib on a 7-, 14-, or 21-day schedule with carboplatin every
3 weeks. Patients underwent [18]fluoro-30-deoxythymidine
(18FLT) positron emission tomography (PET) imaging.
Results. Forty-four patients (39 TNBC, 5 HR positive/HER2 neg-
ative with a defective FA pathway) received a median of 5
cycles (range 1–36). Observed dose-limiting toxicities were
grade (G) 4 thrombocytopenia (n = 4), G4 neutropenia (n = 1),
and G3 akathisia (n = 1). Common grade 3–4 toxicities included
thrombocytopenia, lymphopenia, neutropenia, anemia, and
fatigue. Of the 43 patients evaluable for response, 18.6%
achieved partial response and 48.8% had stable disease.
Median progression-free survival was 18.3 weeks. RP2D of
veliparib was established at 250 mg twice daily on days 1–21
along with carboplatin at area under the curve 5. Patients with
partial response had a significant drop in maximum standard
uptake value (SUVmax) of target lesions between baseline and
early in cycle 1 based on 18FLT-PET (day 7–21; ptrend = .006).
Conclusion. The combination of continuous dosing of veliparib
and every-3-week carboplatin demonstrated activity and an
acceptable toxicity profile. Decrease in SUVmax on
18FLT-PET scan
during the first cycle of this therapy can identify patients who are
likely to have a response. The Oncologist 2020;25:1–12
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Breast Cancer
Implications for Practice: The BROCADE studies suggest that breast cancer patients with BRCA mutation benefit from addition
of veliparib to carboplatin plus paclitaxel. This study demonstrates that a higher dose of veliparib is tolerable and active in com-
bination with carboplatin alone. With growing interest in imaging-based early response assessment, the authors demonstrate
that decrease in [18]fluoro-30-deoxythymidine positron emission tomography (FLT-PET) SUVmax during cycle 1 of therapy is asso-
ciated with response. Collectively, this study established a safety profile of veliparib and carboplatin in advanced breast cancer
while also providing additional data on the potential for FLT-PET imaging modality in monitoring therapy response.
INTRODUCTION
Poly (ADP-ribose) polymerase (PARP) proteins sense single-
strand DNA breaks, signal the presence of DNA damage,
generate linear and branched poly(ADP-ribose) chains, rec-
ognize topoisomerase I cleavage complexes, and facilitate
base excision repair (BER) [1–3]. PARP-1 and PARP-2 are
considered the primary enzymes involved in the repair of
single-stranded DNA breaks through the BER pathways [4],
and enhanced PARP-1 expression and/or activity is one of
the mechanisms by which tumor cells evade apoptosis cau-
sed by DNA-damaging agents [5, 6].
BRCA1 and BRCA2 proteins are essential for homologous
recombination repair, an error-free DNA double-strand break
(DSB) repair pathway. Synthetic lethality due to defects in
homologous recombination and BER that cooperate to repair
DNA damage and dependence of non-homologous end joining
(NHEJ) repair pathway is a popular hypothesis to account for
the increased sensitivity of BRCA1/2-deficient cells to PARP
inhibitors (PARPis) [7–9]. In preclinical studies, BRCA-deficient
cells are more sensitive to platinum drugs than BRCA-proficient
counterparts both in vitro and in vivo, and combining PARPis
and platinum agents was shown to be synergistic [10,
11]. Germline or somatic mutations in BRCA1 or BRCA2 genes
occur in approximately 25% of patients with triple-negative
breast cancer (TNBC), which is more frequent compared with
other breast cancer types. Clinical trials studying regimens con-
taining platinum regimens have also demonstrated that
patients with triple-negative breast cancer respond well to
these agents [12–14].
Although BRCA1/2 alterations are the most well-
established biomarkers for response to PARPi and platinum
chemotherapy, it is clear that a larger subset of non-BRCA1/2
mutated TNBCs as well as some estrogen receptor–positive (ER
+)/human epidermal growth receptor 2–negative (HER2−)
breast cancers could also respond to these agents. BRCA1/2
are part of the Fanconi anemia (FA) network of proteins that
function in DNA-damage response to maintain genome integ-
rity [8, 9, 15]. The FA network of proteins include around
19 members, many of which are mutated in FA syndrome,
including BRCA2/FANCD1, but also additional interacting pro-
teins involved in regulating DNA damage responses like ataxia
telangiectasia, Rad3 related protein, and BRCA1 [16, 17]. This
suggests that tumors with dysfunction in any of the compo-
nents of the FA network may also be particularly susceptible to
PARP inhibition. The common hallmark of defective FA core
complex, such as Fanconi Anemia Group F methylation, is lack
of ubiquitination of FANCD2, leading to lack of FANCD2 foci in
the nuclei of the tumor cells in S phase [17]. Studies provide
evidence that link disruption of FA/BRCA cascade and sporadic
cancers [18, 19] and an association between Fanconi com-
plementaton group D2 (FANCD2) gene variants and sporadic
breast cancer risk has been reported [20]. We hypothesized
that a subset of breast tumors with defective DNA repair aris-
ing from loss of homologous recombination due to inactivation
of the BRCA/FA pathway, so-called “BRCAness,” will be suscep-
tible to treatment with platinum in combination with PARP
inhibitor, similar to hereditary breast and ovarian cancers with
BRCA1/2 germ-line mutations [21]. Therefore, this provides a
rationale to study combinations of platinum drugs with PARP
inhibitors in patients with advanced triple-negative breast can-
cer and/or ER+/HER2− breast cancers with evidence of BRCA/
FA pathway inactivation [22].
3’-deoxy-3’-[F-18] fluorothymidine (18FLT) is a radiolabeled
imaging agent with structural analog of the DNA constituent,
thymidine [23]. The activity of this radiolabeling agent is depen-
dent on cells undergoing DNA replication, and hence, the
uptake of FLT is dependent on the proliferative rate of the cells.
This is in contrast to a more conventional 5-fluorodeoxyglucose
(FDG) positron emission tomography (PET) scan where uptake
of FDG depends on high intake of glucose reflective of
increased metabolic rate and the Warburg effect. Antip-
roliferative treatments that inhibit mitosis will result in marked
decline in uptake of 18FLT and hence can be used to measure
response to therapy by using radioactively labeled 18FLT as a
contrast agent for PET scan (18FLT-PET). Uptake of 18FLT during
therapy with PARP inhibitors and DNA-damaging agents lends
itself well as an attractive imaging modality to study changes in
DNA synthesis and early response to this therapy.
This multicenter phase I study (NCI8609), sponsored by the
Cancer Therapy Evaluation Program (CTEP) at the National
Cancer Institute (NCI), sought to assess the recommended
phase II dose (RP2D) of veliparib on an intermittent (7- or
14-day) or continuous (21-day) schedule in combination with
every-3-week schedule of carboplatin in patients with advanced
breast cancer that was either triple negative or hormone recep-
tor (HR) positive (estrogen and/or progesterone receptor posi-
tive), HER2 negative with defective FA pathway based on lack
of FANCD2 foci in the nuclei of proliferating tumor cells
detected by FA triple stain immunofluorescence (FATSI) assay.
We report the primary endpoint of RP2D and schedule of
veliparib in combination with carboplatin, and secondary end-
points of efficacy. We also report an exploratory endpoint of
correlation of dose and schedule of veliparib and carboplatin
on tumor proliferation and induction DNA damage in the tumor
by analyzing 18FLT PET scans and phosphorylated histone H2AX
(γH2AX) as an indicator of DNA damage in circulating tumor
cells (CTCs), respectively.
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MATERIALS AND METHODS
Patients
Patients eligible for the trial were adult women with meta-
static or locally advanced inoperable breast cancer that ful-
filled one of the three criteria: (a) negative for estrogen,
progesterone, and HER2 receptors (based on American Soci-
ety of Clinical Oncology/College of American Pathologists
guidelines); (b) HR-positive (defined as ER and/or progester-
one receptor positive), HER2-negative breast cancer that is
deficient for the FA pathway based on the FATSI test
(i.e., no FANCD2 foci in nuclei of 100 proliferating tumor cells);
or (c) HER2-negative breast cancer with known germline
BRCA1/2 mutation. HR-positive/HER2-negative patients with-
out known germline BRCA 1 or 2 mutation initially signed a
screening consent for testing their archival tumors for FATSI
and only proceeded with the therapeutic portion of the study
if testing showed deficiency in FA pathway. Other eligibility
criteria requirements included no more than three prior che-
motherapy regimens for metastatic disease, at least 4 weeks
from prior chemotherapy or radiation therapy, an Eastern
Cooperative Oncology Group performance status of 0–2, and
adequate bone marrow, renal, and hepatic function. Patients
with treated central nervous system (CNS) metastasis were eli-
gible. Prior platinum exposure was allowed. Exclusion criteria
included prior therapy with veliparib or other PARP inhibitors
for metastatic disease, uncontrolled intercurrent illness includ-
ing ongoing or active infection, symptomatic congestive heart
failure, unstable angina pectoris, cardiac arrhythmia, psychiat-
ric illness/social situations that would limit compliance with
study requirements, known human immunodeficiency virus
infection, seizures, and uncontrolled CNS metastasis.
Ethics
All patients provided written informed consent. This study
was approved by the local institutional review boards at
Ohio State University (OSU) and each participating site and
conducted in accordance with Good Clinical Practice guide-
lines and the Declaration of Helsinki. This trial was regis-
tered with ClinicalTrials.gov on December 2, 2010, with
identifier NCT01251874.
Study Design and Treatment
This was a multicenter, CTEP-sponsored, single-arm phase I trial
of veliparib on an intermittent (7- or 14-day) or continuous
(21-day) schedule given in combination with carboplatin in
patients with advanced breast cancer. The study used a stan-
dard 3 + 3 dose escalation design. The primary objective was to
determine the recommended phase II dose of veliparib in com-
bination with carboplatin defined as the maximum tolerated
dose (MTD) or the highest dose level (if MTD could not be
determined). Other objectives included assessment of safety
and tolerability and preliminary efficacy of the combination.
Veliparib was initiated at 50 mg, twice daily (b.i.d.),
orally for 1–7 days of 21-day cycles (dose level 1 and 1A). If
tolerated, the schedule of veliparib was escalated to days
1–14 of a 21-day cycle (dose levels 2–5) and then to contin-
uous dosing (dose levels 6–7). Dose of carboplatin was held
stable in all dose levels at area under the curve (AUC) of
5 mg/mL × minute (except for dose level I where the dose
was AUC 6). Dose escalation of veliparib proceeded using a
standard phase I dose escalation in cohorts of 3–6 patients
for dose level (DL) 1–7.
Patients enrolled at Ohio State University underwent
18FDG- and 18FLT-PET/computed tomography (CT) scans, com-
prising 42/44 (95.5%) of all patients enrolled.
Clinical Assessments
Dose-limiting toxicity (DLT) was defined as a significant adverse
event occurring in the first cycle and fulfilling one of the follow-
ing criteria: grade ≥ 3 nonhematologic toxicity (excluding alope-
cia, nausea, vomiting, diarrhea, and tumor pain in patients that
have not received optimal treatment with antiemetics, anti-
diarrheal agents, or analgesics), reversible electrolyte abnormal-
ities of grade ≥ 3 unable to be corrected within 24 hours, grade
4 thrombocytopenia, febrile neutropenia, grade 4 neutropenia
lasting for 7 days or more, or grade 5 toxicity. The MTD and the
RP2D was defined as the highest dose at which no more than
one out of six patients experienced a DLT. Adverse events
were graded according to NCI Common Toxicity Criteria (ver-
sion 3.0). Patients came off study for disease progression,
treatment delay of more than 3 weeks, unacceptable toxic-
ity, or consent withdrawal. Treatment could be delayed for
up to 3 weeks to allow resolution of toxicities, and a patient
could have up to two dose reductions of veliparib and/or
carboplatin, alone or concurrent, to manage toxicity. Dose
reductions of veliparib and/or carboplatin (depending on
attribution) were recommended for grade 3 or 4 febrile neu-
tropenia, grade 4 thrombocytopenia, grade 4 neutropenia
that lasted for 7 or more days, and any grade 3–4 non-
hematological toxicity. Tumor responses were based on blinded
radiologist reader assessment of 18FDG-PET/low-dose diagnos-
tic CT scans obtained at baseline and every three cycles
(9 weeks) thereafter according to the modified response evalu-
ation criteria in solid tumors (mRECIST), version 1.1. A dedicated
and blinded radiologist performed tumor assessments at base-
line and after every three cycles thereafter.
Tumor Tissue Screening: FATSI Assay
Eligible patients with HR-positive, HER2-negative breast cancer
consented to have their formalin-fixed, paraffin embedded
tumor tissue screened for FA functional deficiency using the
FATSI test [24]. The FATSI test uses a triple stain with Ki-67,
40,6-diamidino-2-phenylindole (DAPI), and FANCD2 to iden-
tify FANCD2 foci in the nuclei of proliferating neoplastic
cells. The assay was performed in a Clinical Laboratory
Improvement Amendments (CLIA)–certified laboratory [24]. A
negative FATSI test (i.e., absence of FANCD2 in the nucleus of
100 proliferating cells) would identify patients whose tumors
were deficient in FA pathway [25]. For patients with TNBC,
the FATSI test was performed as a potential biomarker for
response to PARPi therapy.
Gamma H2Ax Assay
CTCs were collected at baseline (day 1 and 3 of cycle 1) and
serially (day 1, 7, and 14 of cycle 2), on day 1 of every 3 cycles,
and at progression, using negative selection technology based
on immunomagnetic tagging and removal of CD45+ cells
[26, 27]. We measured formation of γH2Ax in the CTCs using
© 2020 The Authors.
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an antibody targeting the phospho-histone (Clone JBW301,
Millipore, Darmstadt, Germany cat no. 05-636) [28]. This pri-
mary mouse antibody was subsequently counterstained with
a goat, anti-mouse immunoglobulin G conjugated to Alexa
Fluor 594 (Invitrogen, Carlsbad, California, A-11005).
FLT-PET to Assess Varying Dose Schedules of PARP
Inhibitor
We performed 18FLT-PET/CT imaging at 4 time-points, baseline,
cycle 1, day 7 and 14 (for cohorts receiving veliparib on days
1–7 and days 1–14 of every cycle) or cycle 1, day 14 and
21 (for cohorts treated with veliparib on days 1–21 of every
cycle), and after cycle 3, day 1 to assess change in the uptake
of FLT between patients with and without response. The imag-
ing pharmaceuticals were commercially produced according
to Good Manufacturing Practices (GMP) and under the
Nuclear Regulatory Commission (NRC) license from Cardinal
Health, which has been FDA/NRC approved to produce these
PET radiotracers. The average 18FLT dose used was 10 mCi
with an average FLT injection-to-scan time of 63 minutes.
Patients were imaged using Philips Gemini TF 64 PET/CT sys-
tem (Philips, Amsterdam, The Netherlands) with a whole-body
acquisition (either vertex of the head to the toes at 90 seconds
per bed or vertex of the head to mid-thighs at 90 seconds per
bed followed by mid-thighs to toes at 60 seconds per bed).
PET data were reconstructed using time of flight with a
144 × 144 matrix, 4 mm isometric voxel size, standard recon-
struction with 3 iterations and 33 subsets. Target lesions were
identified by a blinded reader on the baseline 18FDG-PET/CT
enabled by simultaneous PET and CT review. Lesions were
track-matched with the 18FDG-PET/CT and semiquantitatively
assessed using 3D region of interest (ROI) placement in a mat-
ched, blinded fashion. For quantitative assessment of tumor
FDG and FLT uptake, ROIs were placed over tissues with
FDG/FLT activity and SUV measurements determined. Maxi-
mum SUV was calculated from the activity concentration in
the tumor ROIs. Comparison between 18FLT-PET and 18FDG-
PET/CT was prespecified in the study protocol.
Statistical Analysis
The safety population included patients who received at least
one dose of study drug. Adverse events were summarized
descriptively by attribution of study therapy (unlikely, proba-
bly, likely, and definitely related) and grade using Common
Terminology Criteria for Adverse Events (CTCAE) version 3.0.
Laboratory variables were summarized using mean change in
value from baseline to scheduled time points for each dose
level group and 95% confidence interval. Laboratory values
were also categorized according to their CTCAE version 3.0
toxicity grade and tabulated by worst on-study toxicity grade
and dose level group. Progression-free survival was estimated
using Kaplan-Meier methods. All analyses conducted were using
Stata for Windows and R version 3.4.1.
RESULTS
Patient Demographics
Between December 2010 and April 2013, 44 patients with
metastatic or locally advanced inoperable breast cancer were
enrolled from The Ohio State University Comprehensive Can-
cer Center (OSUCCC) and Montefiore Medical Center and
received a median 5 cycles (range 1–36). Patients received up
to three lines of prior chemotherapy regimens for metastatic
disease. Forty-two of 44 (95.5%) patients were enrolled at
OSUCCC, and these patients underwent 18FLT-PET/CT scans in
addition to standard-of-care 18FDG-PET/CT scans. The baseline
characteristics of the patients are outlined in Table 1. Thirty-
nine patients had TNBC and five patients had HR-positive/
HER2-negative metastatic breast cancer (MBC) with functional
deficiency of FA pathway based on negative FATSI assay.
Thirty-four TNBC tumors were tested for FA deficiency using
the FATSI test. Of these, four (11.8%) were found to have
functional deficiency of FA pathway.
Dose-Limiting Toxicities and Safety
All patients were evaluable for toxicity from the time of
their first treatment with veliparib. Three patients were
enrolled on dose level 1 (veliparib 50 mg b.i.d. for 7 days)
with carboplatin at AUC 6 every 21 days. One patient devel-
oped grade (G) 4 thrombocytopenia, and the dose level
expanded to six patients. Two more patients in this dose
level developed DLTs (G4 thrombocytopenia and G4 neutro-
penia). The protocol was subsequently amended, and the
carboplatin dose was reduced to AUC 5 for all subsequent
dose levels. No DLTs were observed in the three patients
subsequently enrolled to dose level 1A with veliparib 50 mg
b.i.d. for 7 days and carboplatin AUC 5. Patients were then
enrolled on escalating doses of veliparib for 14 days, and
MTD was not reached at dose level 5 (Table 2). After fur-
ther discussions with the NCI, the veliparib schedule was
changed to continuous dosing and two dose levels were
planned with this schedule. No DLTs were observed at the
highest planned dose of veliparib (250 mg b.i.d. for 21 days)
Table 1. Patient demographics
Characteristics Patients (n = 44), n (%)
Age, median (range), years 58 (31–77)
ECOG PS
0–1 39 (89)
2 5 (11)
ER/PR status
ER/PR− 39 (89)
ER+ and/or PR+ 5 (11)
No. of metastatic sites
1–3 38 (86)
>3 6 (14)
No. of prior chemo regimens (metastatic)
0–1 29 (66)
2 7 (16)
3 8 (18)
Prior platinum exposure 8 (18)
BRCA1/2 mutation 7 (16)
Defect FA pathway 9 (20)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group per-
formance status; ER, estrogen receptor; FA, Fanconi anemia; PR,
progesterone receptor.
© 2020 The Authors.
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in combination with carboplatin on day 1 (dose level 7).
Dose escalation, number of patients in each cohort, and
DLTs are outlined in Table 2. To better assess tolerability,
we compared the toxicity data between cycle 1 and cycles
2 and 3 within each dose level, and no new DLT was observed
in cycle 2 or 3 as compared with cycle 1. We did not observe
any DLT on dose level 7, but four out of the six patients eventu-
ally required dose reductions of carboplatin and/or veliparib for
thrombocytopenia or nausea. Therefore, the RP2D of veliparib
in combination with carboplatin (AUC5 every 3 weeks) was
determined to be 250 mg b.i.d. on a continuous schedule in
dose level 7 (the highest dose level).
Fifty percent (n = 22) of patients required dose reductions
of either one or both agents primarily for myelosuppression
(in particular, thrombocytopenia). Thirty-three (75%) patients
experienced at least one or more grade 3 or 4 toxicities, which
were attributable to study treatment (Table 3). The most com-
mon and clinically significant grade 3–4 toxicity events were
hematologic and included thrombocytopenia, neutropenia, and
anemia. Among nonhematologic toxicities that were G3 or
higher, the most common were fatigue and vomiting (Table 3).
No grade 5 toxicities were reported. Reasons for discontinuation
of study therapy included disease progression (n = 40), patient
withdrawal (n = 1), adverse events (prolonged neutropenia;
n = 1), and death due to disease progression on study (n = 1).
Efficacy
Of 44 patients, 1 patient on DL 4 withdrew from the study after
receiving only two cycles and was therefore not evaluable for
response. Of the remaining 43 evaluable patients, 18.6% had a
partial response (PR; n = 8); 48.8% had stable disease (SD;
n = 21) as best response (Fig. 1A). Of 21 patients with SD,
10 (23.3%) had SD >24 weeks, providing a clinical benefit rate
(CBR) of 41.9%. The median progression-free survival (PFS) for
all patients who received at least one cycle of therapy was
18.3 weeks (95% confidence interval [CI]: 10.9–22.0 weeks),
and there was no significant difference in PFS across veliparib
dosing schedule (log-rank p = .87; Fig. 1B). Among the eight
patients with PR, median duration of response was 28.3 weeks
(95% CI: 15.4–60.1 weeks). Median overall survival was
62.6 weeks (95% CI: 33.9–87.1 weeks; Fig. 1C).
Deficiency in Homologous Recombination DNA
Repair and Response
Of the nine patients with FATSI demonstrating defective FA
pathway, 22.2% achieved PR (n = 2), 55.6% had SD (n = 5),
Table 2. Summary of dose levels and dose-limiting toxicities
Dose level Carboplatin dose (AUC)
Veliparib dose/schedule
(days in each 21-day cycle) n Dose-limiting toxicities
1 6 50 mg b.i.d. (1–7) 7 G4 thrombocytopenia (n = 2)
G4 neutropenia (n = 1)
1A 5 50 mg b.i.d. (1–7) 3 None
2 5 50 mg b.i.d. (1–14) 6 G4 thrombocytopenia (n = 1)
3 5 100 mg b.i.d. (1–14) 3 None
4 5 150 mg b.i.d. (1–14) 6 G3 akathisia (n = 1)
5 5 200 mg b.i.d. (1–14) 6 G4 thrombocytopenia (n = 1)
6 5 200 mg b.i.d. (1–21) 7 G4 thrombocytopenia (n = 1)
7 5 250 mg b.i.d. (1–21) 6 None
Abbreviations: AUC, area under the curve; G, grade.
Table 3. Overall number of patients with toxicity grade 2 or above
Toxicity Max of G2, n (%) Max of G3, n (%) Max of G4, n (%)
Fatigue 31 (70) 4 (9) 0 (0)
Akathisia 0 (0) 1 (2) 0 (0)
Vomiting 10 (23) 3 (7) 0 (0)
Diarrhea 8 (18) 1 (2) 0 (0)
Dysesthesia 0 (0) 1 (2) 0(0)
Epistaxis 0 (0) 1 (2) 0 (0)
Respiratory, thoracic, and mediastinal disorders 1 (2) 1 (2) 0 (0)
Headache 11 (25) 3 (7) 0 (0)
Hypoglycemia 1 (2) 1 (2) 0 (0)
Thrombocytopenia 14 (32) 15 (34) 9 (20)
Lymphopenia 20 (45) 10 (23) 1 (2)
Neutropenia 20 (45) 8 (18) 2 (5)
Leukopenia 28 (64) 5 (11) 3 (7)
Anemia 30 (68) 8 (18) 0 (0)
Abbreviation: G, grade.
© 2020 The Authors.
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and 22.2% (n = 2) had primary progression. Four of the five
patients with stable disease showed disease stabilization for
>24 weeks (44.4%). Among the seven patients with known
BRCA1/2 mutation, 28.6% (n = 2) had PR, 71.4% (n = 5) had
SD, and 42.9% (n = 3) had SD >6 months. When patients with
tumors deficient in FA pathway based on FATSI testing and
BRCA1/2 mutations were analyzed together (n = 16), 25%
had a PR (n = 4) and 62.5 % had stable disease
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Figure 1. Efficacy and outcomes. (A): Waterfall plot of best response with RECIST percent change indicated on y-axis. Patients with
clinical progression prior to cycle 3 are included at 20% fold change and indicated by asterisk (*). Best response indicated by color
of bars: progressive disease, white; stable disease, grey; partial response, black. (B): Progression-free survival from study entry by
veliparib dosing schedule. Median progression-free survival for all patients who received at least 1 cycle of therapy was 18.3 weeks.
Veliparib dosing indicated by line color: 7-day dosing, red; 14-day dosing, green; 21-day dosing, blue. (C): Overall survival from
study entry. Median overall survival was 62.6 weeks.
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(SD >6 months occurred in 43.8% of patients). One patient
with BRCA1 mutation achieved durable partial response to
study therapy and received a total of 95 cycles of treatment.
The patient was taken off the study after experiencing
treatment-related thrombocytopenia (despite dose reductions
and multiple delays of carboplatin dosing) and was subse-
quently diagnosed with myelodysplastic syndrome. The
myelodysplastic syndrome was assessed as possibly related to
study therapy.
18FLT-PET Imaging: Correlation with 18FDG-PET and
RECIST Measurement
18FLT-PET imaging was obtained successfully in all patients
treated at OSU (42/44 total patients) with the proliferative
whole-body mapping revealing expected uptake in the bone
marrow, spleen, and liver (supplemental online Fig. 1). There
were no toxicities attributable to administration of 18FLT. The
use of two distinct PET radiotracers in this study facilitates
evaluation of distinct biological processes in cancer cells, spe-
cifically, metabolic activity (18FDG-PET) and proliferation
(18FLT-PET). We first evaluated the correlation between the
two tracers (Fig. 2A). Evaluating the primary target lesion at
both baseline (BL) and first planned imaging (cycle 3 day
1 [C3]), we show that there is overall good correlation
between maximum standard uptake value (SUVmax) of
18FDG-
and 18FLT-PET (Spearman’s rho = 0.62, p = 4.1e-07). We eval-
uated BL and C3 time points independently and demon-
strated similar correlations (supplemental online Fig. 2A, 2B).
To investigate dynamic changes over time on therapy,
we evaluated the association of fold change from BL to first
planned imaging (C3) for 18FLT-PET, 18FDG-PET, and REC-
ISTv1.1 (Fig. 2B–2D). 18FLT-PET and 18FDG-PET primary tar-
get lesion SUVmax fold change from BL to C3 showed similar
correlation to the simple SUVmax values (Spearman’s rho =
0.61, p = 7.3e-04). When comparing RECISTv1.1 measure-
ments BL:C3 fold change with the PET metrics, 18FLT-PET
primary target lesion SUVmax fold change showed lower corre-
lation (Spearman’s rho = 0.43, p = .03) than 18FDG-PET primary
target lesion SUVmax (Spearman’s rho = 0.77, p = 6.7e-06). Of
note, both patients not enrolled at OSU had stable disease as
best response.
Serial 18FLT-PET Imaging and Association with
Response
We performed 18FLT-PET scan at four time points: (a) baseline
(BL); (b) cycle 1 day 7 (time point 1 [T1]); (c) day 14 for
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Figure 2. 18FLT-PET imaging: correlation with 18FDG-PET and RECIST measurement. (A): Scatter plot of 18FLT-PET SUVmax of target
lesion versus 18FDG-PET SUVmax of the same target lesion at baseline (“BL”; indicated in blue) and cycle 3 day 1 (“C3”; indicated in
orange). Line of best fit indicated. (B-D): Scatter plot of fold change from BL to C3 of 18FLT-PET SUVmax of target lesion versus
18FDG-PET SUVmax of the same target lesion (B),
18FLT-PET SUVmax of target lesion versus RECISTv1.1 (C), and
18FDG-PET SUVmax of
target lesion versus RECISTv1.1 measurement (D). For all comparisons, correlation evaluated by Spearman’s rank correlation coeffi-
cient with p value indicated.
Abbreviations: BL, baseline; C3, cycle 3 day 1; FDG, 5-fluorodeoxyglucose; FLT, fluoro-30-deoxythymidine; SUVmax, maximum stan-
dard uptake value.
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cohorts receiving veliparib on days 1–14 (time point 2 [T2]) of
every cycle or (b) cycle 1, day 14 (time point 1 [T1]); (c) day 21
(time point 2 [T2]) for cohorts treated with veliparib on days
1–21 of every cycle; and (d) after cycle 3 (C3) to assess change
in the uptake of 18FLT between patients with and without
response. The change in SUVmax on
18FLT-PET between base-
line and follow-up scans did not depend on dose or schedule
of veliparib (n = 24). Comparing the linear trend across four
time points in responders versus others, there was a statisti-
cally significant drop in 18FLT uptake in the responders
(p = .006), whereas there was no trend in patients who
achieved stable disease or had progressive disease (PD) as
best response (Fig. 3A, top panel). Among responders, patients
had a rapid decrease in 18FLT uptake by T1 (cycle 1 day 7 or
day 14) with little change to T2 (cycle 1 day 14 or day 21) or
C3 (Fig. 3A, bottom panel). Nonresponders showed little
change in 18FLT uptake across time points. As an exploratory
analysis, we also evaluated fold change in 18FLT for each of six
possible pairs: (a) BL:T1; (b) BL:T2; (c) BL:C3; (d) T1:T2; (e) T1:
T3; (f) T2:T3 (supplemental online Fig. 2C, 2D). For responders
(PR) versus nonresponders (SD + PD), fold change from
baseline to T1, T2, or C3 were all associated with response
(nominal p < .05) but not after multiple test correction (all
false discovery rate adjusted p > .05), whereas fold change
from T1 or T2 showed no association (supplemental online
Fig. 2C). For clinical benefit versus not, there was no signifi-
cant association between fold change and clinical benefit
(supplemental online Fig. 2D). We then evaluated 18FLT-PET
SUVmax at BL versus C3, compared with
18FDG-PET SUVmax
and RECISTv1.1 total measurement (Fig. 3B, 3D). At C3, all
three metrics demonstrated significant drop among
responders, whereas those with stable disease or progres-
sive disease did not show a significant decrease by any
metric.
Circulating Tumor Cells
Peripheral blood for CTCs were obtained serially in 36 patients
enrolled at OSU, with 32 patients having at least three serial
samples. Although CTC values did not have any correlation
with response groups, gamma H2Ax in CTCs at baseline
showed higher trend among those with a PR (p = .02), and
these values tended to be numerically higher during cycle 2 in
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Figure 3. Early change in 18FLT-PET SUVmax. (A): Top panel shows
18FLT-PET SUVmax of target lesion from baseline (“BL”), to day 7
(“T1”) to day 14 or 21 timepoint (“T2”), to cycle 3 day 1 timepoint (“C3”). Patients are grouped by best response, partial response
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this group (p = .08), suggesting higher induction of DNA dam-
age (supplemental online Fig. 3).
DISCUSSION
Preclinical studies have shown that PARP1 inhibitors potenti-
ate cytotoxicity when combined with platinum chemotherapy
agents (cisplatin or carboplatin), which induce DNA damage
through adducts and cross-linking [29]. Veliparib (ABT-888) is
an efficient oral PARP inhibitor that targets PARP1 and PARP2,
the primary enzymes involved in DNA repair [30]. Specifically,
veliparib inhibits both baseline and cytotoxic-induced PARP
activity in in vivo tumor models and thus provides evidence of
the ability of veliparib to target PARP [31, 32]. Single-agent
PARP inhibitor was approved for patients with BRCA-deficient
hereditary advanced ovarian cancers and breast cancers
[33, 34]. To date, combination of PARP inhibitors and other
agents are tested in clinical trials, but none of them have yet
received FDA approval. Neoadjuvant studies in breast cancer
have shown that platinum agents are highly effective in triple-
negative cancers, particularly the BRCA-associated tumors. This
is consistent with preclinical BRCA mutant models demonstrat-
ing the combination of veliparib and carboplatin being more
effective than either drugs alone or combination of cisplatin
plus veliparib [35]. Recently, the I-SPY 2 Trial showed that
veliparib–carboplatin added to standard therapy resulted in
higher rates of pathological complete response than standard
therapy alone in TNBC [12, 36, 37]. These data clearly point
out that in tumors with defective homologous recombination,
DNA-damaging agents in combination with PARP inhibition are
highly effective and show promise as future therapies in the
clinic. The BrighTNess trial tested addition of veliparib to car-
boplatin or carboplatin alone to neoadjuvant chemotherapy in
patients with stage II–III triple-negative breast cancer (not
selected for BRCA1/2 mutation) and showed that addition of
carboplatin but not veliparib resulted in higher pathologic
complete response rate [36]. However, both these studies
used a low dose of veliparib at 50 mg p.o. twice daily on a con-
tinuous schedule along with carboplatin in the early breast
cancer setting.
Our multi-institutional phase I study demonstrated that
veliparib in combination with carboplatin was well tolerated.
Veliparib at 250 mg daily on a continuous schedule given along
with carboplatin at AUC of 5 on day 1 of a 21-day cycles was the
RP2D and schedule based on 3 + 3 dose escalation schema. This
was the highest planned dose (250 mg b.i.d. daily), and we did
not do further dose escalations because most patients on this
dose level required dose reductions during later cycles owing to
toxicities. Patients tolerated the combination well overall, and
the most common grade 3 or higher toxicities were hemato-
logic, such as neutropenia, anemia, and thrombocytopenia.
The most common nonhematologic toxicities were fatigue and
vomiting. Our RP2D was higher than that established by the
California Consortium Trial (NCT01149083) in patients with
BRCAmutation–associated MBC, where the RP2D of veliparib
with carboplatin was established at 150 mg b.i.d. (continuous
dosing). The DLTs and toxicities reported in this study were sim-
ilar to ours, with grade 3 thrombocytopenia and neutropenia
being themost frequent [38]. Another phase I study of veliparib
combined with cisplatin and vinorelbine in advanced TNBC
and/or BRCA mutation–associated cancer established 300 mg
b.i.d. (days 1–14 on a 21-day cycle) as the RP2D. This study also
reported hematological toxicities as the most frequent
DLTs [39].
Our trial is unique in not only focusing on all TNBC but also
including HR-positive patients with defective FA pathway. In
addition, our phase I study investigated three different sched-
ules including days 1–7, days 1–14, and continuous treatment
of veliparib. Based on our study, in the metastatic setting,
patients are able to tolerate a higher dose of veliparib (250 mg
daily) on a continuous schedule with carboplatin every 3 weeks
provided that the dose of carboplatin is kept at an AUC of 5.
The overall CBR in our patient population was 41.9%
(CBR = PR + SD ≥6 months). Higher clinical benefit was seen in
patients with germline BRCA1/2 mutation (CBR 71.5%) and
defective FA pathway (CBR 66.6%). This is similar to the CBR
reported by other investigators. Somlo et al. reported a 51%
CBR in their phase I study with veliparib and carboplatin in
BRCAmutation carriers with MBC [38]. The phase II portion of
this trial tested the efficacy of single-agent veliparib at 300 mg
b.i.d. in germline BRCA1/2 mutation carriers, with those pro-
gressing on single-agent veliparib treated with the combina-
tion carboplatin and veliparib at 150 mg b.i.d. Interestingly,
the median PFS of the 30 patients treated with this combina-
tion after progression on single-agent veliparib was low at
1.8 months (95% CI: 1.4–2.3). This suggests that combining
veliparib with a platinum agent earlier in the disease course
may be a better strategy. Another study reported a 35% over-
all response rate in all patients (TNBC) but showed a 57%
response rate among patients with BRCA mutation treated
with the combination of cisplatin, vinorelbine, and veliparib
[39]. A phase II trial of the combination of paclitaxel, car-
boplatin, and veliparib in BRCA1/2 mutation carriers resulted
in a 77.8% response rate (BROCADE) [40]. A subsequent phase
III, double-blind, randomized study (BROCADE3) showed a
nearly 2-month improvement in progression-free survival with
the addition of veliparib (120 mg b.i.d. on days −2 to 5) to
standard doses of carboplatin and paclitaxel (compared with
placebo added to carboplatin and paclitaxel) in patients with
HER2-negative metastatic breast cancer and germline
BRCA1/2mutation [41].
The question then is whether sporadic cancers with defec-
tive homologous recombination would benefit from similar
strategy, and furthermore, what would be the effective and yet
tolerable chemotherapy to use in combination with PARP inhib-
itors. Phenotypic and mechanistic studies have shown that
sporadic breast tumors with “BRCAness” show inactivation of
components of this pathway either through silencing of BRCA
or dysfunction of other genes in the cascade of DNA repair
pathway such as FA pathway [17]. Our phase I trial included
patients with advanced TNBC (many of whom have the
“BRCAness” phenotype) and those with HR-positive advanced
breast cancer with defective FA pathway to establish the dose,
schedule, safety, and preliminary efficacy of combining veliparib
with carboplatin. Our study has shown that combining car-
boplatin with veliparib is effective and well tolerated, particu-
larly in tumors with DNA repair deficiency. In fact, we have
preliminarily found in the current study that patients with BRCA
1 and 2 mutations or those that have tumors with FA pathway
deficiency experienced greater responses (PR and SD of 25%
© 2020 The Authors.
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and 62.5% compared with 18% and 48%, respectively, in all
study patients). Veliparib is the weakest PARP trapping agent in
contrast to other PARP inhibitors such as talazoparib or
olaparib. This likely results in less hematologic toxicities associ-
ated with use of veliparib but probably adversely affects its anti-
tumor efficacy. It is not clear whether combination of platinum
agents with other PARP inhibitors that have stronger PARP trap-
ping properties would result in higher efficacy compared with
similar combinations with veliparib.
A unique aspect of our study is the inclusion of functional
imaging using 18FLT-PET scans at early time points to noninva-
sively assess reduction in proliferation rate and compare this
with 18FDG-PET scans. Increased uptake of 18FLT is seen in cells
that express high levels of thymidine kinase 1, the key enzyme
in the pyrimidine salvage pathway of DNA synthesis [42], hence
correlating with increased cell proliferation. The SUVmax mea-
surements on 18FLT-PET-CT have been shown to correlate with
response to therapy in breast cancer [23]. We performed 18FLT-
PET scans at four early time points (baseline, cycle 1 day 7 and
14, cycle 1 day 14 and 21, and cycle 3 day 1) as a tool to deter-
mine the impact of dose and schedule of veliparib on the prolif-
eration rate of metastatic sites, and we found that the SUVmax
on FLT-PET scan did not vary with dose or schedule (7 vs. 14 vs.
21 days) of veliparib. We demonstrated that among re-
sponders, drop in 8FLT uptake is rapid in many patients—within
7 days—implicating a potential early imaging marker of re-
sponse. Three other studies in metastatic and primary breast
cancer have demonstrated that changes in FLT uptake in the pri-
mary or metastatic sites after one cycle of chemotherapy corre-
lated with best response (metastatic setting) or neoadjuvant
chemotherapy response (primary setting) [43–45]. The largest
study, performed in the neoadjuvant setting, suggested that
18FLT-PET had robust correlation with tissue KI67 staining after
chemotherapy but more modest correlation with KI67 at base-
line or overall tumor response [45]. By performing 18FLT-PET
imaging along with 18FDG-PET imaging, this rich data set also
allowed comparison of PET radiotracers—we found that
although 18FLT-PET and 18FDG-PET were overall correlated,
there are differences, and we are currently evaluating whether
thesemodalitiesmay be complementary. Our study has demon-
strated that performing serial 18FLT-PET scans is feasible with-
out adverse effects and can be a noninvasive tool to assess
early response and proliferation rates.
We also obtained CTC at multiple time points to assess
the impact of dose and schedule of veliparib on the induc-
tion of γH2Ax as a marker of DNA damage. Phosphorylation
of histone H2Ax on serine 139 (γH2AX) occurs at sites
flanking DNA DSBs and provides a measure of the number of
DSBs within a cell [46]. Although the dose and schedule of
veliparib did not affect the induction of γH2Ax, we did find
that the responders had a numerically higher baseline γH2Ax
in CTCs and there was evidence of further induction of
γH2Ax in these patients at the end of cycle 2. This is not sur-
prising as baseline levels of γH2Ax in breast tumors have
been associated with triple-negative breast cancer and worse
prognosis indicating higher proliferative rates [47]. Larger
studies need to be done to confirm the use of higher γH2AX
in CTCs as a biomarker of response to DNA-damaging agents
and PARPis.
CONCLUSION
Our phase I, dose-finding study of varying dose and sched-
ule of veliparib along with carboplatin identified 250 mg
b.i.d. daily as the recommended phase II dose and demon-
strated safety and tolerability in patients with sporadic and
BRCA-mutated TNBC and in patients with HR-positive MBC
who had a functional deficiency of FA pathway as detected
by FATSI assay. Furthermore, our study showed that use of
novel functional FLT-PET imaging as a tool to assess reduc-
tion in proliferative rate in the tumor and early response is
feasible. The single-agent PARP inhibitors olaparib and
talazoparib are approved for the management of BRCA-
mutated MBC. Our study provides rationale to study plati-
num/PARPi combination in other tumor subtypes as well.
ACKNOWLEDGMENTS
The study is supported by U01 CA076576. R.W. is supported by
Translational Grant K12 CA133250 in experimental therapeutics
from the National Cancer Institute and Cancer Clinical Investiga-
tor Team Leadership Award P30CA016058-42S2. D.G.S. is
supported by Susan G. Komen Career Catalyst Research Award.
All clinical trial data will be deposited in accordance with CTEP,
NCI, and NIH guidelines.
AUTHOR CONTRIBUTIONS
Conception/design: Robert Wesolowski, Michael R. Grever, Michael
V. Knopp, Bhuvaneswari Ramaswamy
Provision of study material or patients: Maryam B. Lustberg, Ewa Mrozek,
Rachel M. Layman, Erin Macrae, Eleni Andreopoulou, Joseph Sparano,
Charles L. Shapiro, Miguel Angel Villalona-Calero, Susan Geyer, Alice Chen
Collection and/or assembly of data: Daniel G. Stover, Abigail Shoben,
Meng Zhao
Data analysis and interpretation: Daniel G. Stover, Abigail Shoben, Meng
Zhao, Wenrui Duan, Jun Zhang, Nathan Hall, Chadwick L. Wright, Susan
Gillespie, Michael Berger, Jeffrey J. Chalmers, Priya Balasubramanian,
Brandon L. Miller, Peter Amaya
Manuscript writing: Robert Wesolowski, Daniel G. Stover, Maryam B. Lustberg,
Abigail Shoben, Meng Zhao, Ewa Mrozek, Rachel M. Layman, Erin Macrae,
Wenrui Duan, Jun Zhang, Nathan Hall, Chadwick L. Wright, Susan Gillespie,
Michael Berger, Jeffrey J. Chalmers, Alahdra Carey, Priya Balasubramanian,
Brandon L. Miller, Peter Amaya, Eleni Andreopoulou, Joseph Sparano, Charles
L. Shapiro, Miguel Angel Villalona-Calero, Susan Geyer, Alice Chen, Michael
R. Grever, Michael V. Knopp, Bhuvaneswari Ramaswamy
Final approval of manuscript: Robert Wesolowski, Daniel G. Stover, Maryam
B. Lustberg, Abigail Shoben, Meng Zhao, Ewa Mrozek, Rachel M. Layman,
Erin Macrae, Wenrui Duan, Jun Zhang, Nathan Hall, Chadwick L. Wright,
Susan Gillespie, Michael Berger, Jeffrey J. Chalmers, Alahdra Carey, Priya Bal-
asubramanian, Brandon L. Miller, Peter Amaya, Eleni Andreopoulou, Joseph
Sparano, Charles L. Shapiro, Miguel Angel Villalona-Calero, Susan Geyer, Alice
Chen, Michael R. Grever, Michael V. Knopp, Bhuvaneswari Ramaswamy
DISCLOSURES
Robert Wesolowski: Acerta, AstraZeneca (RF), PUMA, Pfizer (C/A);
Miguel Angel Villalona-Calero: Merck (RF [institution]);
Bhuvaneswari Ramaswamy: Pfizer (RF), Eisai, Pfizer (C/A). The
other authors indicated no financial relationships.
(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert
testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/
inventor/patent holder; (SAB) Scientific advisory board
© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Phase I Study of Veliparib and Carboplatin10
REFERENCES
1. Helleday T, Petermann E, Lundin C et al. DNA
repair pathways as targets for cancer therapy.
Nat Rev Cancer 2008;8:193–204.
2. Lord CJ, Ashworth A. The DNA damage
response and cancer therapy. Nature 2012;
481:287–294.
3. Chaudhuri AR, Hashimoto Y, Herrador R et al.
Topoisomerase I poisoning results in PARP-
mediated replication fork reversal. Nat Struct
Mol Biol 2012;19:417–423.
4. Ame JC, Spenlehauer C, de Murcia G. The
PARP superfamily. Bioessays 2004;26:882–893.
5. Schreiber V, Ame JC, Dolle P et al. Poly(ADP-
ribose) polymerase-2 (PARP-2) is required for
efficient base excision DNA repair in association
with PARP-1 and XRCC1. J Biol Chem 2002;277:
23028–23036.
6. Memisoglu A, Samson L. Base excision repair
in yeast and mammals. Mutat Res 2000;451:
39–51.
7. Kaelin WG Jr. The concept of synthetic lethal-
ity in the context of anticancer therapy. Nat Rev
Cancer 2005;5:689–698.
8. Farmer H, McCabe N, Lord CJ et al. Targeting
the DNA repair defect in BRCA mutant cells
as a therapeutic strategy. Nature 2005;434:
917–921.
9. Bryant HE, Schultz N, Thomas HD et al. Specific
killing of BRCA2-deficient tumours with inhibitors
of poly(ADP-ribose) polymerase. Nature 2005;434:
913–917.
10. Bhattacharyya A, Ear US, Koller BH et al.
The breast cancer susceptibility gene BRCA1 is
required for subnuclear assembly of Rad51 and
survival following treatment with the DNA cross-
linking agent cisplatin. J Biol Chem 2000;275:
23899–23903.
11. Tassone P, Tagliaferri P, Perricelli A et al.
BRCA1 expression modulates chemosensitivity of
BRCA1-defective HCC1937 human breast cancer
cells. Br J Cancer 2003;88:1285–1291.
12. Sikov WM, Berry DA, Perou CM et al.
Impact of the addition of carboplatin and/or
bevacizumab to neoadjuvant once-per-week pac-
litaxel followed by dose-dense doxorubicin and
cyclophosphamide on pathologic complete
response rates in stage II to III triple-negative
breast cancer: CALGB 40603 (Alliance). J Clin
Oncol 2015;33:13–21.
13. Tutt A, Ellis P, Kilburn L et al. TNT: A random-
ized phase III trial of carboplatin (C) compared
with docetaxel (D) for patients with metastatic or
recurrent locally advanced triple negative or
BRCA1/2 breast cancer (CRUK/07/012). Abstract
S3-01 presented at: 2014 San Antonio Breast Can-
cer Symposium.
14. Tutt A, Cheang MCU, Kilburn L et al. BRCA1
methylation status, silencing and treatment
effect in the TNT trial: A randomized phase III
trial of carboplatin compared with docetaxel for
patients with metastatic or recurrent locally
advanced triple negative or BRCA1/2 breast can-
cer (CRUK/07/012). Abstract S6-01 presented at:
2016 San Antonio Breast Cancer Symposium.
15. Barroso E, Pita G, Arias JI et al. The Fanconi
anemia family of genes and its correlation with
breast cancer susceptibility and breast cancer
features. Breast Cancer Res Treat 2009;118:
655–660.
16. Wang W. Emergence of a DNA-damage
response network consisting of Fanconi anaemia
and BRCA proteins. Nat Rev Genet 2007;8:735–748.
17. Ceccaldi R, Sarangi P, D’Andrea AD. The Fan-
coni anaemia pathway: New players and new func-
tions. Nat Rev Mol Cell Biol 2016;17:337–349.
18. Lyakhovich A, Surralles J. Disruption of the
Fanconi anemia/BRCA pathway in sporadic can-
cer. Cancer Lett 2006;232:99–106.
19. Tischkowitz M, Xia B, Sabbaghian N et al.
Analysis of PALB2/FANCN-associated breast can-
cer families. Proc Natl Acad Sci U S A 2007;104:
6788–6793.
20. Barroso E, Milne RL, Fernandez LP et al.
FANCD2 associated with sporadic breast cancer
risk. Carcinogenesis 2006;27:1930–1937.
21. Telli ML, Stover DG, Loi S et al. Homologous
recombination deficiency and host anti-tumor
immunity in triple-negative breast cancer. Breast
Cancer Res Treat 2018;171:21–31.
22. Belli C, Duso BA, Ferraro E et al. Homolo-
gous recombination deficiency in triple negative
breast cancer. Breast 2019;45:15–21.
23. Bollineni VR, Kramer GM, Jansma EP et al. A
systematic review on [(18)F]FLT-PET uptake as a
measure of treatment response in cancer
patients. Eur J Cancer 2016;55:81–97.
24. Duan W, Gao L, Zhao W et al. Assessment
of FANCD2 nuclear foci formation in paraffin-
embedded tumors: A potential patient-
enrichment strategy for treatment with DNA
interstrand crosslinking agents. Transl Res 2013;
161:156–164.
25. Duan W, Gao L, Aguila B et al. Fanconi ane-
mia repair pathway dysfunction, a potential ther-
apeutic target in lung cancer. Front Oncol 2014;
4:368.
26. Lustberg MB, Balasubramanian P, Miller B
et al. Heterogeneous atypical cell populations
are present in blood of metastatic breast cancer
patients. Breast Cancer Res 2014;16:R23.
27. Balasubramanian P, Lang JC, Jatana KR et al.
Multiparameter analysis, including EMT markers,
on negatively enriched blood samples from
patients with squamous cell carcinoma of the
head and neck. PLoS One 2012;7:e42048.
28. Garcia-Villa A, Balasubramanian P, Miller BL
et al. Assessment of gamma-H2AX levels in circu-
lating tumor cells from patients receiving chemo-
therapy. Front Oncol 2012;2:128.
29. Alli E, Sharma VB, Sunderesakumar P et al.
Defective repair of oxidative DNA damage in triple-
negative breast cancer confers sensitivity to inhibi-
tion of poly(ADP-ribose) polymerase. Cancer Res
2009;69:3589–3596.
30. Penning TD, Zhu GD, Gandhi VB et al. Dis-
covery of the Poly(ADP-ribose) polymerase
(PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-
1H-benzimidazole-4-carboxamide (ABT-888) for
the treatment of cancer. J Med Chem 2009;52:
514–523.
31. Kummar S, Kinders R, Gutierrez ME et al.
Phase 0 clinical trial of the poly (ADP-ribose)
polymerase inhibitor ABT-888 in patients with
advanced malignancies. J Clin Oncol 2009;27:
2705–2711.
32. Kummar S, Ji J, Morgan R et al. A phase I
study of veliparib in combination with metro-
nomic cyclophosphamide in adults with refrac-
tory solid tumors and lymphomas. Clin Cancer
Res 2012;18:1726–1734.
33. Litton J, Rugo HS, Ettl J et al. Abstract
GS6-07: EMBRACA: A phase 3 trial comparing
talazoparib, an oral PARP inhibitor, to physician’s
choice of therapy in patients with advanced
breast cancer and a germline BRCA mutation.
Abstract presented at: 2017 San Antonio Breast
Cancer Symposium; December 5–9, 2017; San
Antonio, TX.
34. Robson M, Im SA, Senkus E et al. Olaparib
for metastatic breast cancer in patients with a
germline BRCA mutation. N Engl J Med 2017;
377:523–533.
35. Clark CC, Weitzel JN, O’Connor TR. Enhance-
ment of synthetic lethality via combinations of
ABT-888, a PARP inhibitor, and carboplatin
in vitro and in vivo using BRCA1 and BRCA2 iso-
genic models. Mol Cancer Ther 2012;11:
1948–1958.
36. Loibl S, O’Shaughnessy J, Untch M et al.
Addition of the PARP inhibitor veliparib plus car-
boplatin or carboplatin alone to standard neo-
adjuvant chemotherapy in triple-negative breast
cancer (BrighTNess): A randomised, phase 3 trial.
Lancet Oncol 2018;19:497–509.
37. von Minckwitz G, Schneeweiss A, Loibl S
et al. Neoadjuvant carboplatin in patients with
triple-negative and HER2-positive early breast
cancer (GeparSixto; GBG 66): A randomised
phase 2 trial. Lancet Oncol 2014;15:747–756.
38. Somlo G, Frankel PH, Arun BK et al. Efficacy
of the PARP inhibitor veliparib with carboplatin
or as a single agent in patients with germline
BRCA1- or BRCA2-associated metastatic breast
cancer: California Cancer Consortium Trial
NCT01149083. Clin Cancer Res 2017;23:
4066–4076.
39. Rodler ET, Kurland BF, Griffin M et al. Phase
I study of veliparib (ABT-888) combined with cis-
platin and vinorelbine in advanced triple-
negative breast cancer and/or BRCA mutation-
associated breast cancer. Clin Cancer Res 2016;
22:2855–2864.
40. Han HS, Dieras V, Robson M et al. Veliparib
with temozolomide or carboplatin/paclitaxel versus
placebo with carboplatin/paclitaxel in patients with
BRCA1/2 locally recurrent/metastatic breast can-
cer: Randomized phase II study. Ann Oncol 2018;
29:154–161.
41. Dieras VC, Han HS, Kaufman B et al. Phase
3 study of veliparib with carboplatin and pacli-
taxel in HER2-negative advanced/metastatic
gBRCA-associated breast cancer. Ann Oncol
2019;30(suppl 5):v851–v934.
42. Shields AF. PET imaging with 18F-FLT and
thymidine analogs: Promise and pitfalls. J Nucl
Med 2003;44:1432–1434.
43. Kenny L, Coombes RC, Vigushin DM et al.
Imaging early changes in proliferation at 1 week
post chemotherapy: A pilot study in breast can-
cer patients with 3’-deoxy-3’-[18F]fluoro-
thymidine positron emission tomography. Eur J
Nucl Med Mol Imaging 2007;34:1339–1347.
© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
www.TheOncologist.com
Wesolowski, Stover, Lustberg et al. 11
44. Pio BS, Park CK, Pietras R et al. Usefulness of 3’-
[F-18]fluoro-3’-deoxythymidine with positron emis-
sion tomography in predicting breast cancer
response to therapy. Mol Imaging Biol 2006;8:36–42.
45. Kostakoglu L, Duan F, Idowu MO et al. A
phase II study of 3’-deoxy-3’-18f-fluorothymidine
PET in the assessment of early response of
breast cancer to neoadjuvant chemotherapy:
Results from ACRIN 6688. J Nucl Med 2015;56:
1681–1689.
46. Palla VV, Karaolanis G, Katafigiotis I et al.
gamma-H2AX: Can it be established as a classical
cancer prognostic factor? Tumour Biol 2017;39:
1010428317695931.
47. Nagelkerke A, van Kuijk SJA, Sweep FCGJ
et al. Constitutive expression of gamma-H2AX
has prognostic relevance in triple negative breast
cancer. Radiother Oncol 2011;101:39–45.
See http://www.TheOncologist.com for supplemental material available online.
© 2020 The Authors.
The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Phase I Study of Veliparib and Carboplatin12
